

- Page 36, line 3, change "protien" to --protein--;
line 6, change "matricies" to --matrices--;
line 10, change "seive" to --sieve--;
line 18, change "Publisrers" to --Publishers--;
- Page 39, line 1, change "futher" to --further--;
- Page 40, line 27, change "Futhermore" to --Furthermore--;
- Page 45, line 11, change "seperating" to --separating--;
line 12, change "anology" to --analogy--;
line 13, change "significaltly" to --significantly--;
- Page 79, line 30, change "Immnl.," to --Immunol.,--;
- Page 90, line 3, after "Dr. Nichols" delete the extra space before the comma;
- Page 92, line 21, change "preformed" to --performed--;
- Page 95, line 8, change "descibed" to --described--;
- Page 98, line 6, change "petide" to --peptide--;
- Page 99, line 11, change "sequentially" to --sequentially--;
line 21, change "Optoinally" to --Optionally--;
line 21, change "Cysteins" to --cysteines--; and
line 23, change "cysteins" to --cysteines--.

IN THE CLAIMS

Please cancel claims 2, 5-6, 8 and 10-12 and amend the remaining claims as follows:

1. (Amended) An isolated substantially homogeneous human mpl ligand [polypeptide] wherein the amino acid sequence of the ligand consists of amino acid residues 1 to X of Fig. 8, where X is residue 153-332.
3. (Amended) The mpl ligand [polypeptide] of Claim 1 selected from the group consisting of
[(a) the polypeptide that is isolated from a mammal;
(b)](a) the [polypeptide] mpl ligand that is made by recombinant means; and
[(c)] (b) the [polypeptide] mpl ligand that is made by synthetic means.
4. (Amended) The mpl ligand [polypeptide] of Claim 1 [selected from the group consisting of
(a) the polypeptide that is human; and
(b) the polypeptide] that is non-immunogenic in a human.